Absci Corporation (ABSI)
NASDAQ • Healthcare
Last close at October 23, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Nov 12
in 18 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Absci’s adjusted EPS topped expectations while revenue fell year over year in the second fiscal quarter of 2026, reported August 11, 2026. Revenue declined 46.4% to roughly $0.3 million (from $593,000.00 a year ago), reflecting the company’s small base of reported revenue from its biologic drug discovery and cell line engineering work, and gross profit matched revenue at roughly $0.3 million. On profitability, operating income was about -$34.2 million, and net income improved 8.6% year over year to roughly -$33.2 million (from -$30.6 million a year ago). On the bottom line versus consensus, adjusted EPS of -$0.18 topped the -$0.19 estimate by $0.01. For the next period, consensus calls for EPS of -$0.19.
Next report — what to expect
Absci Corporation (ABSI) is set to report earnings on November 11, 2026. Wall Street is looking for EPS of -$0.19 on revenue of $697,567.00. For trailing context, revenue fell -46.4% year over year last quarter. Absci has beaten EPS in 3 of its 8 most recent quarters.
About Absci Corporation
Absci Corporation develops potential biologic medicines and cell lines for manufacturing in the United States as a small-cap biotechnology company listed on NASDAQ under the ticker ABSI. Its work centers on potential biologic medicines and the cell lines used in manufacturing them, and the company was founded in 2011.
Today's Snapshot
The day ended with ABSI 2% lower at 9.18, in line with a weaker sector. Trading was lighter than usual, with volume about half of its usual level.
Trading Volume
Below 10d avg (3.3M)
1.8M
vs S&P 500 Today
Underperforming Market
-1.51%
Updated: October 23, 2026 at 20:14 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$6.65 - $9.38Sell
- RSI (14)48.44Neutral
- Stochastic %K (14, 3, 3)37.40Neutral
- MACD Level (12, 26)-0.09Sell
Peers & Related Assets
Get premium market insights delivered directly to your inbox.